Liver Illness and Psychiatric Patients

Authors Information
Article Notes and Dates
To Cite : Carrier P, Debette-Gratien M, Girard M, Jacques J, Nubukpo P, et al. Liver Illness and Psychiatric Patients, Hepat Mon. 2016 ;16(12):e41564. doi: 10.5812/hepatmon.41564.
Copyright: Copyright © 2016, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnote
References
  • 1. Youssef NA, Abdelmalek MF, Binks M, Guy CD, Omenetti A, Smith AD, et al. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int. 2013; 33(7): 1062-70[DOI][PubMed]
  • 2. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011; 8(2): 114-26[DOI][PubMed]
  • 3. Selim K, Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology. 1999; 29(5): 1347-51[DOI][PubMed]
  • 4. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005; 2(5): 141[DOI][PubMed]
  • 5. Chaudhary RK, Perry E, Cleary TE. Prevalence of hepatitis B infection among residents of an institution for the mentally retarded. Am J Epidemiol. 1977; 105(2): 123-6[PubMed]
  • 6. Hughes E, Bassi S, Gilbody S, Bland M, Martin F. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry. 2016; 3(1): 40-8[DOI][PubMed]
  • 7. Cividini A, Pistorio A, Regazzetti A, Cerino A, Tinelli C, Mancuso A. Hepatitis C virus infection among institutionalised psychiatric patients: a regression analysis of indicators of risk. J Hepatol. 1997; 27(3): 455‑63[DOI]
  • 8. Chaudhary RK, Perry E, Hicks F, MacLean C, Morbey M. Hepatitis B and C infection in an institution for the developmentally handicapped. N Engl J Med. 1992; 327(27): 1953[DOI][PubMed]
  • 9. Goodkin K. Assessing the prevalence of HIV, HBV, and HCV infection among people with severe mental illness. Lancet Psychiatry. 2016; 3(1): 4-6[DOI][PubMed]
  • 10. Essock SM, Dowden S, Constantine NT, Katz L, Swartz MS, Meador KG, et al. Risk factors for HIV, hepatitis B, and hepatitis C among persons with severe mental illness. Psychiatr Serv. 2003; 54(6): 836-41[DOI][PubMed]
  • 11. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012; 57(6): 1379-90[DOI][PubMed]
  • 12. Lang JP, Michel L, Melin P, Schoeffler M, Gauchet A, Rousseaux C, et al. Management of psychiatric disorders and addictive behaviors in patients with viral hepatitis C in France. Gastroenterol Clin Biol. 2009; 33(1 Pt 1): 1-7[DOI][PubMed]
  • 13. Modabbernia A, Poustchi H, Malekzadeh R. Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review. Hepat Mon. 2013; 13(1): 8340[DOI][PubMed]
  • 14. Zanini B, Benini F, Pigozzi MG, Furba P, Giaco E, Cinquegrana A, et al. Addicts with chronic hepatitis C: difficult to reach, manage or treat? World J Gastroenterol. 2013; 19(44): 8011-9[DOI][PubMed]
  • 15. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann Intern Med. 2016; 165(9): 625-34[DOI][PubMed]
  • 16. Sogni P, Carrieri MP, Fontaine H, Mallet V, Vallet-Pichard A, Trabut JB, et al. The role of adherence in virological suppression in patients receiving anti-HBV analogues. Antivir Ther. 2012; 17(2): 395-400[DOI][PubMed]
  • 17. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990; 264(19): 2511-8[PubMed]
  • 18. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry. 1997; 54(4): 313-21[DOI][PubMed]
  • 19. Bruha R, Dvorak K, Petrtyl J. Alcoholic liver disease. World J Hepatol. 2012; 4(3): 81-90[DOI][PubMed]
  • 20. Dumortier J, Dharancy S, Cannesson A, Lassailly G, Rolland B, Pruvot FR, et al. Recurrent alcoholic cirrhosis in severe alcoholic relapse after liver transplantation: a frequent and serious complication. Am J Gastroenterol. 2015; 110(8): 1160-6[DOI][PubMed]
  • 21. Hezode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology. 2008; 134(2): 432-9[DOI][PubMed]
  • 22. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006; 58(3): 389-462[DOI][PubMed]
  • 23. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology. 2007; 46(1): 122-9[DOI][PubMed]
  • 24. Despres JP, Golay A, Sjostrom L, Rimonabant in Obesity-Lipids Study G. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005; 353(20): 2121-34[DOI][PubMed]
  • 25. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008; 372(9651): 1733-45[DOI][PubMed]
  • 26. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet. 1992; 340(8816): 384-7[DOI][PubMed]
  • 27. Mallat A, Dhumeaux D. Cocaine and the liver. J Hepatol. 1991; 12(3): 275-8[DOI][PubMed]
  • 28. Payance A, Scotto B, Perarnau JM, de Muret A, Bacq Y. Severe chronic hepatitis secondary to prolonged use of ecstasy and cocaine. Clin Res Hepatol Gastroenterol. 2013; 37(5): 109-13[DOI][PubMed]
  • 29. Riordan SM, Williams R. Liver disease due to illicit substance use. Addict Biol. 1998; 3(1): 47-53[DOI][PubMed]
  • 30. European Association for Study of L. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol. 2012; 56(3): 671-85[DOI][PubMed]
  • 31. Zimbrean PC, Schilsky ML. The spectrum of psychiatric symptoms in Wilson's disease: treatment and prognostic considerations. Am J Psychiatry. 2015; 172(11): 1068-72[DOI][PubMed]
  • 32. Schilsky ML, Scheinberg IH, Sternlieb I. Liver transplantation for Wilson's disease: indications and outcome. Hepatology. 1994; 19(3): 583-7[DOI][PubMed]
  • 33. Eftekar M, Pun P. Psychiatric risk factors predicting post-liver transplant physical and psychiatric complications: a literature review. Australas Psychiatr. 2016; [DOI]
  • 34. Corruble E, Barry C, Varescon I, Falissard B, Castaing D, Samuel D. Depressive symptoms predict long-term mortality after liver transplantation. J Psychosom Res. 2011; 71(1): 32-7[DOI][PubMed]
  • 35. Errichiello L, Picozzi D, de Notaris EB. Prevalence of psychiatric disorders and suicidal ideation in liver transplanted patients: a cross-sectional study. Clin Res Hepatol Gastroenterol. 2014; 38(1): 55-62[DOI][PubMed]
  • 36. Krahn LE, DiMartini A. Psychiatric and psychosocial aspects of liver transplantation. Liver Transpl. 2005; 11(10): 1157-68[DOI][PubMed]
  • 37. Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. Aliment Pharmacol Ther. 2014; 40(8): 880-92[DOI][PubMed]
  • 38. Gulmez SE, Larrey D, Pageaux GP, Bernuau J, Bissoli F, Horsmans Y, et al. Liver transplant associated with paracetamol overdose: results from the seven-country SALT study. Br J Clin Pharmacol. 2015; 80(3): 599-606[DOI][PubMed]
  • 39. Hayward KL, Powell EE, Irvine KM, Martin JH. Can paracetamol (acetaminophen) be administered to patients with liver impairment? Br J Clin Pharmacol. 2016; 81(2): 210-22[DOI][PubMed]
  • 40. Dargan PI, Jones AL. Acetaminophen poisoning: an update for the intensivist. Crit Care. 2002; 6(2): 108-10[DOI][PubMed]
  • 41. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis. 1986; 6(2): 97-106[DOI][PubMed]
  • 42. Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet. 2002; 359(9306): 558-63[DOI][PubMed]
  • 43. Loria P, Adinolfi LE, Bellentani S, Bugianesi E, Grieco A, Fargion S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis. 2010; 42(4): 272-82[DOI][PubMed]
  • 44. Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol. 2013; 10(11): 666-75[DOI][PubMed]
  • 45. de Ledinghen V, Vergniol J, Capdepont M, Chermak F, Hiriart JB, Cassinotto C, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014; 60(5): 1026-31[DOI][PubMed]
  • 46. Cales P, Boursier J, Chaigneau J, Laine F, Sandrini J, Michalak S, et al. Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. Liver Int. 2010; 30(9): 1346-54[DOI][PubMed]
  • 47. Elwing JE, Lustman PJ, Wang HL, Clouse RE. Depression, anxiety, and nonalcoholic steatohepatitis. Psychosom Med. 2006; 68(4): 563-9[DOI][PubMed]
  • 48. Weinstein AA, Kallman Price J, Stepanova M, Poms LW, Fang Y, Moon J, et al. Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. Psychosomatics. 2011; 52(2): 127-32[DOI][PubMed]
  • 49. Fukudo S, Suzuki J, Tanaka Y, Iwahashi S, Nomura T. Impact of stress on alcoholic liver injury; a histopathological study. J Psychosom Res. 1989; 33(4): 515-21[DOI][PubMed]
  • 50. Ishida JH, Peters MG, Jin C, Louie K, Tan V, Bacchetti P, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol. 2008; 6(1): 69-75[DOI][PubMed]
  • 51. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care. 2000; 23(7): 934-42[PubMed]
  • 52. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003; 54(3): 317-29[DOI][PubMed]
  • 53. Bremmer MA, Beekman AT, Deeg DJ, Penninx BW, Dik MG, Hack CE, et al. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord. 2008; 106(3): 249-55[DOI][PubMed]
  • 54. Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, et al. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology. 2007; 133(2): 608-18[DOI][PubMed]
  • 55. Papazoglou I, Berthou F, Vicaire N, Rouch C, Markaki EM, Bailbe D, et al. Hypothalamic serotonin-insulin signaling cross-talk and alterations in a type 2 diabetic model. Mol Cell Endocrinol. 2012; 350(1): 136-44[DOI][PubMed]
  • 56. Danan G. [Definitions and assessment criteria of acute drug-induced hepatitis. Conclusions of an International Consensus Meeting]. Gastroenterol Clin Biol. 1991; 15(11): 845-8[PubMed]
  • 57. Lo Re V3, Haynes K, Forde KA, Goldberg DS, Lewis JD, Carbonari DM, et al. Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model. Clin Gastroenterol Hepatol. 2015; 13(13): 2360-8[DOI][PubMed]
  • 58. Sabate M, Ibanez L, Perez E, Vidal X, Buti M, Xiol X, et al. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther. 2007; 25(12): 1401-9[DOI][PubMed]
  • 59. Danan G, Bernuau J, Moullot X, Degott C, Pessayre D. Amitriptyline-induced fulminant hepatitis. Digestion. 1984; 30(3): 179-84[DOI][PubMed]
  • 60. Remy AJ, Larrey D, Pageaux GP, Ribstein J, Ramos J, Michel H. Cross hepatotoxicity between tricyclic antidepressants and phenothiazines. Eur J Gastroenterol Hepatol. 1995; 7(4): 373-6[PubMed]
  • 61. Sedky K, Nazir R, Joshi A, Kaur G, Lippmann S. Which psychotropic medications induce hepatotoxicity? Gen Hosp Psychiatry. 2012; 34(1): 53-61[DOI][PubMed]
  • 62. Lourenco MT, Kennedy SH. Desvenlafaxine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2009; 5: 127-36[PubMed]
  • 63. Soliman HM, Wagih HM, Algaidi SA, Hafiz AH. Histological evaluation of the role of atypical antipsychotic drugs in inducing non-alcoholic fatty liver disease in adult male albino rats (light and electron microscopic study). Folia Biol (Praha). 2013; 59(5): 173-80[PubMed]
  • 64. Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker WW. Hepatotoxicity of clozapine. J Clin Psychopharmacol. 1997; 17(4): 314-7[PubMed]
  • 65. El Hajj I, Sharara AI, Rockey DC. Subfulminant liver failure associated with quetiapine. Eur J Gastroenterol Hepatol. 2004; 16(12): 1415-8[PubMed]
  • 66. Erdogan A, Atasoy N, Akkurt H, Ozturk D, Karaahmet E, Yalug I, et al. Risperidone and liver function tests in children and adolescents: a short-term prospective study. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(3): 849-57[DOI][PubMed]
  • 67. Bryant A3, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology. 1996; 46(2): 465-9[PubMed]
  • 68. Jacques J, Carrier P, Debette-Gratien M, Sobesky R, Loustaud-Ratti V. [Hepatic encephalopathy]. Presse Med. 2016; 45(1): 46-59[DOI][PubMed]
  • 69. Luef GJ, Waldmann M, Sturm W, Naser A, Trinka E, Unterberger I, et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol. 2004; 55(5): 729-32[DOI][PubMed]
  • 70. Higuchi S, Yano A, Takai S, Tsuneyama K, Fukami T, Nakajima M, et al. Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. Toxicol Sci. 2012; 130(1): 4-16[DOI][PubMed]
  • 71. Bosdure E, Cano A, Roquelaure B, Reynaud R, Boyer M, Viard L, et al. [Oxcarbazepine and DRESS syndrome: a paediatric cause of acute liver failure]. Arch Pediatr. 2004; 11(9): 1073-7[DOI][PubMed]
  • 72. Makin AJ, Fitt S, Williams R, Duncan JS. Fulminant hepatic failure induced by lamotrigine. BMJ. 1995; 311(7000): 292[DOI][PubMed]
  • 73. Chui LK, Pelot D. Hepatic enzyme elevations associated with baclofen. Clin Pharm. 1984; 3(2): 196-7[PubMed]
  • 74. Verrico MM, Nace DA, Towers AL. Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy. J Am Geriatr Soc. 2000; 48(12): 1659-63[DOI][PubMed]
  • 75. Demolis JL, Angebaud P, Grange JD, Coates P, Funck-Brentano C, Jaillon P. Influence of liver cirrhosis on sertraline pharmacokinetics. Br J Clin Pharmacol. 1996; 42(3): 394-7[DOI][PubMed]
  • 76. Franz CC, Egger S, Born C, Ratz Bravo AE, Krahenbuhl S. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2012; 68(2): 179-88[DOI][PubMed]
  • 77. Thyrum PT, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry. 2000; 24(4): 521-33[DOI][PubMed]
  • 78. Tapper EB, Risech-Neyman Y, Sengupta N. Psychoactive Medications Increase the Risk of Falls and Fall-related Injuries in Hospitalized Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2015; 13(9): 1670-5[DOI][PubMed]
  • 79. Tiseo PJ, Vargas R, Perdomo CA, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. Br J Clin Pharmacol. 1998; 46 Suppl 1: 51-5[DOI][PubMed]
  • 80. Stewart KE, Levenson JL. Psychological and psychiatric aspects of treatment of obesity and nonalcoholic fatty liver disease. Clin Liver Dis. 2012; 16(3): 615-29[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check